The Operating Theatre Journal - Journal - Page 9
®
Introducing Nuvis, the cleanest
solution in arthroscopy today.
Single-use
always sterile,
always readyno delays
Patented 4K
technology
for sharper,
cleaner images
Integrated LED
Coollite™
for high definition
illumination
Cordless Light &
Self-Powered
no messy cords in
operating theatre
Low cost-point
no added
expense per
surgery
NUVIS® is a next-generation arthroscopic solution from Integrated Endoscopy.
Its technological advancements include 4K imaging, an integrated HD light
source and a single-use design that ensures it’s always sterile, always ready.
These innovations redefine the gold-standard in ergonomic, wireless operation.
To learn more about NUVIS’ revolutionary performance advantages,
contact us today.
Info@hospitalinnovations.co.uk | www.hospitalinnovations.com
01443 719 555
Robocath performs world’s First-In-Human remote robotic coronary
angioplasty between two Chinese cities 1,700 miles apart
Procedure took place simultaneously in Beijing and Urumqi, carried out entirely via 5G connection with R-One™ robotic platform
Robocath, a company that designs, develops and markets innovative
robotic solutions for treating cardiovascular diseases, today announces
it performed a First-in-Human robotic coronary angioplasty from 1,700
miles (2,800 km) away. Two interventional cardiologists, Prof. Yundai
Chen in Beijing and Prof. Yining Yang in Urumqi, the capital of the
Xinjiang Uygur Autonomous Region, performed the procedure. This
world-昀椀rst, performed entirely using a 5G connection, paves the way
for more long-distance endovascular procedures in the future.
The cardiologists performed the procedure last July on a 59-yearold patient admitted to the People’s Hospital of Xinjiang Uygur
Autonomous Region in Urumqi. Thanks to the R-One – Robocath’s 昀椀rst
commercial robotic platform – Prof. Yundai Chen was able to perform
a complete coronary angioplasty, assisted by Prof. Yining Yang and his
medical team, who were on site with the patient in the catheterization
laboratory. Technical and verbal communication between the two
operators was maintained throughout the procedure thanks to the
stability and reliability of the 5G network, eliminating possible latency
effects in the imaging and sound system.
“I feel honored to have been part of this world-昀椀rst-in-human
procedure in the 昀椀eld of interventional medicine. Its success opens
up the possibility of future long-distance cardiovascular treatment
options. China currently has over 2,000 catheterization laboratories,
but that’s still not enough to cover the whole country. With the help
of robotics, we believe we can treat more patients faster and more
effectively. Another advantage is that the robot can position the stent
with exceptional accuracy. I’m excited to continue this partnership,
which I believe marks the start of a new era for treatment in our 昀椀eld,”
said Prof. Yundai Chen, interventional cardiologist in Beijing.
“This procedure shows the world the feasibility and safety of coronary
angioplasty at very great distances, thanks to a perfectly stable and
controlled communication system. The team at the People’s Hospital of
Xinjiang Uygur Autonomous Region is extremely proud to have played
a part in this phenomenal technological achievement, which has the
potential to revolutionize interventional medicine,” added Prof. Yining
Yang, interventional cardiologist at the People’s Hospital of Xinjiang
Uygur Autonomous Region, in Urumqi.
“At Robocath, we are committed to developing smart connected robotic
platforms that improve the treatment of cardiovascular diseases –
the leading cause of death worldwide. Currently, these emergencies,
including stroke, can remain untreated within a reasonable timeframe
due to geographical remoteness and the small number of dedicated care
centers. Robotic solutions remove these barriers entirely and ensure
patients are treated quickly and to a very high standard by medical
experts. From a specialist medical center, physicians will be able to
perform operations on patients located in outlying emergency units.
There are still several challenges to face before this type of treatment
can be widely adopted, particularly in terms of organization and legal
liability. However, we are convinced that the future of interventional
medicine lies with robotics. Its remote connection module will
considerably accelerate expansion, particularly in vast territories such
as China,” stated Lucien Goffart, CEO at Robocath.
“This procedure marks the ful昀椀llment of an ambition we set ourselves
when we founded Robocath 15 years ago; to guarantee equal access
to care for all, in all locations. I’m proud to see the success of this
procedure – a world-昀椀rst – which was made possible thanks to Cathbot,
our joint-venture based in China.
Robotic technology responds directly to the challenges faced by modern
public healthcare systems and will enable the greatest possible number
of patients to access the best treatment available. As with other
breakthroughs, I am convinced that public authorities will rise to this
technological challenge and initiate the necessary changes, given the
major societal bene昀椀t that long-distance robotic treatment of vascular
emergencies represents today,” concluded Philippe Bencteux, president
and founder of Robocath.
www.robocath.com
Find out more 02921 680068 • e-mail admin@lawrand.com
Issue 400
When responding to articles please quote ‘OTJ’
January
2024
9